Introduction
Chronic inflammation underlies a variety of human diseases, including cardiovascular disease and inflammatory bowel disease. Consumption of the n-3 polyunsaturated fatty acids (PUFAs), eicosapentaenoic acid (C20:5 n-3) and docosahexaenoic acid (C22:6 n-3), as mainly present in fish, may be associated with anti-inflammatory effects (Calder, 1997 (Calder, , 2006 . A generally accepted mechanism behind this is that a higher dietary intake of eicosapentaenoic acid increases its inflammatory cell membrane concentration at the expense of arachidonic acid (C20:4 n-6). This can lead to a shift in the production of cytokines through an altered eicosanoid production, resulting in a less proinflammatory state (Calder and Grimble, 2002) . Numerous studies have investigated the effects of n-3 PUFA on inflammatory markers in different types of populations. If we only focus on studies on inflammatory markers in healthy individuals, the evidence of effects of n-3 PUFA on inflammatory markers is not very solid, as is shown in two recent reviews (Fritsche, 2006; Sijben and Calder, 2007) . Fritsche (2006) concluded that n-3 PUFA supplementation studies with healthy human individuals did not provide consistent or compelling evidence to support the hypothesis that dietary PUFAs affect inflammatory responses in a manner that is likely to have clinical consequences. Moreover, Sijben and Calder (2007) concluded in their review that most studies in healthy individuals did not show effects on immune markers such as cytokine production by lymphocytes and monocytes. In most of the studies evaluating the effect of n-3 PUFA on inflammatory cytokines, isolated cells stimulated with stimuli like endotoxin were studied, whereas studying circulating soluble markers in serum might be more closely linked with an in vivo situation. In addition, in most of these studies, only a few inflammatory markers were studied, similar to a recent study by Yusof et al. (2008) who studied six systemic inflammatory markers, or a study by Fujioka et al. (2006) who studied only two inflammatory markers. Moreover, as cytokines are interrelated in regulatory networks, a wide spectrum of cytokines, rather than a few selected cytokines, should be analyzed, including their interrelationships. Besides cytokines, other forms of soluble inflammatory markers could be added to this spectrum of inflammatory markers, such as chemokines and cell adhesion molecules. Chemokines are chemotactic cytokines that regulate the process of inflammation by controlling the homeostasis of circulation of leukocytes (Luster, 1998) . Soluble forms of cell adhesion molecule-1 and vascular cell adhesion molecule-1 are found in serum and are elevated during inflammatory conditions (Gearing and Newman, 1993) . So far, few studies have addressed the effects of fish oil supplementation on cytokines, in combination with cell adhesion molecules or chemokines, in a healthy, middleaged population, showing conflicting results: some studies showed a decrease in cell adhesion molecules (Thies et al., 2001; Yusof et al., 2008) , whereas other studies showed no effect (Murphy et al., 2007; Damsgaard et al., 2008) . Therefore, our main aim was to study the effects of fish oil supplementation on a large range of serum inflammatory markers including cytokines, chemokines and cell adhesion molecules, using a multiplex immunoassay in middle-aged individuals. In addition, we evaluated the interrelationships of these inflammatory markers in the two treatment groups.
Participants and methods
Participants and study design This study was primarily designed to investigate the effects of fish oil supplementation on heart rate variability and baroreflex sensitivity in healthy individuals, and power calculations were based on the primary outcome of changes in heart rate variability and baroreflex sensitivity (Geelen et al., 2003) .
We included 81 individuals aged 50-70 years in a parallel, double-blind, placebo-controlled intervention trial that was performed between January and May 2001. After a run-in period of 4 weeks, in which participants were provided with placebo capsules and were instructed not to consume fish, seafood or fish oil capsules, participants were randomized to receive either a daily dose of 3.5 g of fish oil or placebo oil (high oleic sunflower oil) during a 12-week intervention period. Participants were stratified by habitual fish consumption, diastolic blood pressure and gender and then randomized to receive either fish oil or placebo by a person independent of the study. Both researchers and participants were blinded to the treatment, and fish oil and placebo capsules were indistinguishable from each other.
The daily dose of fish oil provided approximately 700 mg of eicosapentaenoic acid, 560 mg of docosahexaenoic acid and 260 mg of other n-3 fatty acids (in total 1.5 g/day n-3 PUFA). Exclusion criteria were mainly related to problems of the cardiovascular system, including past or present cardiovascular disease, diabetes mellitus and hypertension (4170 mm Hg systolic or 4100 mm Hg diastolic). Only postmenopausal women not receiving hormone replacement therapy were included. Compliance was checked and confirmed by analyzing n-3 fatty acids in serum cholesteryl esters and by counting the number of leftover capsules. The study protocol was approved by the Medical Ethical Committee of Wageningen University and all participants gave written informed consent.
Characteristics of the study population including height, weight and physical activity (Washburn et al., 1993; Schuit et al., 1997) were measured at baseline and published previously (Geelen et al., 2003) . Habitual fish intake was assessed by interviewing the participants using a questionnaire on the frequency of fish intake. Participants also kept a diary on their general health status. High sensitivity serum C-reactive protein concentrations were measured at baseline and after intervention, using an enzyme immunoassay, and results were published before (Geelen et al., 2004) .
Measurements of inflammatory markers
Non-fasting blood samples were collected at the start and end of intervention for each participant at the same time of day before and after intervention. Moreover, participants were instructed to eat low-fat meals on the day of the blood draw. Blood samples were stored at À80 1C until further processing. Multiplex immunoassays were performed as previously described (de Jager et al., 2003 (de Jager et al., , 2005 to measure serum concentrations of soluble interleukin (IL)-1a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8 (or CXCL8), IL-10, IL-12p70, IL-13, tumor necrosis factor-a, interferon-g, macrophage migration inhibitory factor, monocyte chemoattractant protein-1 (CCL2), intracellular adhesion molecule-1, vascular adhesion molecule-1, macrophage inflammatory protein-1-a (CCL3), regulated upon activation, normal T-cell expressed and secreted (RANTES or CCL5) and eotaxin (CCL11). Samples were analyzed using the Bio-plex system in combination with the Bio-plex Manager software version 3.0 (Bio-Rad Laboratories, Hercules, CA, USA). Concentrations of analytes were quantified using a standard curve that was generated using five parametric curve fittings to the series of known concentrations of analytes. Owing to technical reasons, the results of one participant were excluded from analyses ( Figure 1 ).
Intra-assay variability expressed as coefficient of variation of the multiplex immunoassay has been published previously and varied between 6.5 and 22% (de Jager et al., 2003 (de Jager et al., , 2005 .
Statistical methods
We excluded three individuals from the analyses on the basis of a serum concentration of C-reactive protein 410 mg/l, either at baseline or at the end of the intervention, resulting in a study population of 77 individuals (Figure 1 ). These three excluded individuals reported flu-like symptoms in their diary preceding blood collection (Geelen et al., 2004) . We assigned a value equal to half of the detection limit of a given cytokine or chemokine if any values were below detection limit. A sensitivity analysis was performed to determine whether the results were sensitive to this arbitrary choice by comparing analyses in which one-quarter of the detection limit was assigned to such data points.
As data were not normally distributed, medians and interquartile ranges (25th percentile, 75th percentile) are presented for baseline and end values of all inflammatory markers. The end values of the outcomes were used in a model of analysis of covariance, comparing the fish oil supplemented group with the placebo group adjusted for baseline values.
As an additional and explorative analysis, we applied principal component analysis (PCA) to analyze the patterns of cytokines, chemokines and cell adhesion molecules by using the Factor procedure in SAS (Garson and David, 2008) . We also included C-reactive protein measures that were measured and published previously in these patterns (Geelen et al., 2004) . Responses of inflammatory markers (afterbefore measurement) were entered into the model, and on the basis of an evaluation of eigenvalues and the Scree plot, patterns were derived and rotated using the VARIMAX option in SAS (SAS Institute Inc., Cary, NC, USA). Individual factor loadings for the main three factors were plotted to explore whether two clusters would be visible, representing the two treatment groups.
For inflammatory markers, we considered a P-value of o0.01 as statistically significant, as we performed multiple comparisons. All statistical analyses were carried out using the SAS statistical software program (version 9.1, SAS Institute Inc.).
Results
Baseline characteristics of the participants are presented in Table 1 . Participants receiving fish oil and placebo were similar in terms of gender, age, body mass index, habitual fish intake, smoking status and degree of physical activity. One serious adverse event was reported during the study, but this was not related to the study. This person was not included in the analysis.
Serum cytokine concentrations at baseline and after the 12-week intervention are presented in Table 2 , and serum chemokines and cell adhesion molecules are presented in Table 3 . The percentage of participants with a measurement below the detection limit varied from 0% for some cytokines and adhesion molecules to 87% for IL-10 (Table 2 and 3) .
Serum concentrations of cytokines after treatment did not differ statistically significantly between the fish oil-treated and placebo-treated participants (Table 2 ). In addition, serum concentrations of chemokines and cell adhesion molecules were not significantly different between the two intervention groups after the 12-week fish oil intervention (Table 3) . Overall, it seemed that all serum inflammatory markers were increased rather than decreased after fish oil supplementation than with placebo; however, these increases were not statistically significant. Results from the sensitivity analysis, using a different value for replacing values below the detection limit, were comparable with the original analysis (data not shown). 
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Principal component analysis
In Figure 2 , the individual results of the PCA are plotted for the first three factor loadings, each dot represents one person. Factor 1 consisted of IL-1b, IL-2, IL-5, IL-6, IL-10, IL-13, tumor necrosis factor-a, interferon-g, macrophage inflammatory protein-1a, IL-8 and vascular adhesion molecule , and explained 43.4% of the total variance. Factor 2 Fish oil and inflammatory markers GK Pot et al consisted of IL-1a, IL-2, IL-4 and macrophage migration inhibitory factor, and explained 17.6% of the total variance. Factor 3 consisted of monocyte chemoattractant protein-1 and RANTES, and explained 10.7% of the total variance. The first three factors together explained 71.7% of the total variance. We observed no explicit clusters for participants treated with either fish oil or placebo (Figure 2) .
Discussion
This randomized, double-blind placebo-controlled intervention trial showed no effect of 1.5 g n-3 PUFA daily for 12 weeks on serum inflammatory markers in healthy middleaged individuals. If anything, there was a trend that all serum inflammatory markers tended to increase after fish oil supplementation, but this was not statistically significant. No marked differences in patterns of serum inflammatory markers between treatment groups were observed. Our results contribute to the body of evidence that, in studies with healthy individuals, generally no effects of n-3 PUFA supplementation on inflammatory markers were observed (Fritsche, 2006; Sijben and Calder, 2007) . Healthy individuals, similar to the participants of this study, generally have low levels of serum inflammatory markers. Thus, the chance that low levels of inflammation are reduced by an intervention with fish oil is very small. In addition, low levels of serum inflammatory markers are not easy to detect, which is reflected in the number of values below detection limit in this study. Chemokines and cell adhesion molecules were in the detectable range, but no effect of fish oil supplementation was observed for these inflammatory markers. Therefore, it may well be possible that in a middleaged population such as this, no beneficial effect of fish oil supplementation on serum inflammatory markers is to be expected, although it may be possible that other markers of immune function, such as the expression of cell adhesion markers on monocytes and respiratory burst response in neutrophils, could be affected, as was shown in previous studies (Hughes et al., 1996; Rees et al., 2006; Luu et al., 2007) .
A limitation of our study is that blood samples were collected throughout the day, which could have introduced some variation due to possible natural fluctuations in cytokine concentrations (Petrovsky et al., 1998) . To counteract this potential problem, blood samples per participant were collected at the same time of day before and after intervention. In addition, fluctuations in cytokine concentrations could be expected after meals, especially high-fat meals (Nappo et al., 2002; Jellema et al., 2004; Lundman et al., 2007) . However, participants were asked to consume low-fat meals before the measurement. Nevertheless, the additional variation caused by fluctuations over the day may have weakened our results. Moreover, we used a multiplex immunoassay rather than an enzyme-linked immunosorbent assay, which is generally considered the gold standard. Nevertheless, the multiplex immunoassay used in our study was validated against enzyme-linked immunosorbent assay (de Jager et al., 2003) and sensitivity, accuracy and reproducibility of the two methods were similar. Using different methods of measuring inflammatory markers could lead to different results (Cooper et al., 1993; Calder, 2007) . However, if we compare studies using different methods for measuring inflammatory markers in healthy individuals, the conclusions are the same for these studies, that is, no beneficial effects of fish oil were observed in healthy individuals.
A clear strength of our study is the compliance of our participants to the intervention, which was very high (Geelen et al., 2003) . Another advantage is that we measured a large panel of serum inflammatory markers, including chemokines, cell adhesion molecules and, previously, C-reactive protein. This might better reflect the overall inflammatory response compared with other studies, investigating only a few markers. When studying a large range of markers, it should be kept in mind that correction for multiple testing might be necessary. In this study, we choose a P-value of o0.01 as statistically significant. We chose not to use the Bonferroni correction, as this might be too conservative given that the inflammatory markers are also interrelated (Aickin and Gensler, 1996) . In addition, we studied the coherence and interrelationships of the inflammatory markers using PCA. While studying patterns of inflammatory markers, one could make the distinction Figure 2 Three-dimensional plot of factor loadings, with each colour representing a different treatment group (treatment 0 ¼ placebo, 1 ¼ fish oil). The numbers in the figure are factor loadings for each inflammatory marker after Varimax rotation. The patterns were derived using principal component analysis. Factor 1 consists of interleukin (IL)-1b, IL-2, IL-5, IL-6, IL-10, IL-13, tumor necrosis factor-a, interferon-g, macrophage inflammatory protein1a, IL-8 and vascular adhesion molecule (and explains 43.4% of total variance). Factor 2 consists of IL-1a, IL-2, IL-4 and macrophage migration inhibitory factor (and explains 17.6% of the total variance). Factor 3 consists of monocyte chemoattractant protein-1 and RANTES (and explains 10.7% of the total variance).
Fish oil and inflammatory markers GK Pot et al between pro-and anti-inflammatory markers. However, we could not identify any specific pro-or anti-inflammatory pattern, or specific patterns for chemokines or cell adhesion molecules. It could be argued that the classification of proand anti-inflammatory is too simplistic as the function of a specific cytokine depends on the amount, the target cell, the producing cell and the sequence of actions of cytokines. Furthermore, we used PCA to analyze the possible patterns in our dataset, as PCA is a commonly used method to analyze possible patterns (Garson and David, 2008) . We realize that other types of factor analysis can be applied as well, although these other methods have other underlying assumptions. Owing to the number of participants, the PCA was rather explorative.
For future large-scale studies, the use of the multiplex immunoassay has two big advantages: first, only 50 ml of biological fluid is necessary for the measurement of multiplex immunoassays and second, its relatively low costs. Future observational and experimental studies could use this approach to measure a large range of inflammatory markers using factor or cluster analysis. It would be most interesting to include individuals with an inflamed status, such as patients with cardiovascular disease or inflammatory bowel disease, especially as inflammatory markers are elevated and possible patterns of interrelationships are easier to detect. In addition, besides serum inflammatory markers, more local markers of inflammation, such as markers in colonic tissue, could be considered to study the effects of diet on inflammation (Calder, 2007) .
In conclusion, the results of this randomized, doubleblind, placebo-controlled intervention are in agreement with previous studies that suggest that fish oil supplementation has no effect on serum inflammatory markers in a healthy middle-aged population. Moreover, no effects on the interrelationships of these inflammatory markers were found.
